The company has announced the appointment of two new board members, Erik Walldén and Stefan Löfås.
Both members will play a key role in bolstering the full execution of the company’s corporate strategy to grow business in the research market and develop much needed solutions for clinical diagnostics, it reports.
During 30 years of international life science industry management, Erik Walldén has been responsible for the global launch of a number of technologies, establishing and restructuring companies, implementation of targeted issues and stock market listings. Previously, he was the CEO of Gyros, Affibody Holding, Biacore International and Pyrosequencing and has held senior positions at PerSeptive Biosystems, Pharmacia Biosensor and Pharmacia Biotech. Moreover, Walldén is presently Chairman of the Board at Cavidi and Lumicks, and holds board level positions at Virgin Instruments, Beactica and CellSeed.
Stefan Löfås was the Chief Scientific Officer at Biacore International and until recently the Scientific Director at GE Healthcare Bio-Sciences with strategic responsibility for technology development.
“We are delighted that both Erik Walldén, and Stefan Löfås are joining the board. Their appointments will play a crucial role in the realization of the ambitious corporate strategy that we set ourselves – enabling Symcel to increase the flow of business from the R&D sector and expand into the clinical diagnostics space”, commented Jesper Ericsson, CEO of Symcel.
